Polaris Capital Management LLC Sells 10,000 Shares of Elevance Health, Inc. $ELV

Key Points

• Polaris Capital Management sold 10,000 shares of Elevance, trimming its position by 11.9% to 73,941 shares worth $25.92 million, making ELV about 2.2% of Polaris’s holdings (its 24th largest holding).
• Elevance beat Q1 estimates with EPS of $12.58 vs. $10.74 and revenue of $49.49 billion vs. $48.21 billion, and the company raised its 2026 adjusted EPS outlook (to at least $26.75), signaling stronger-than-expected performance.
• Dividend and risks: Elevance declared a quarterly dividend of $1.72 (ex-dividend June 10), about a 2.0% yield, but faces an investor securities probe that adds legal uncertainty amid mixed analyst sentiment.

Polaris Capital Management LLC decreased its position in Elevance Health, Inc. (NYSE:ELV - Free Report) by 11.9% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 73,941 shares of the company's stock after selling 10,000 shares during the quarter. Elevance Health accounts for approximately 2.2% of Polaris Capital Management LLC's holdings, making the stock its 24th biggest holding. Polaris Capital Management LLC's holdings in Elevance Health were worth $25,920,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Physician Wealth Advisors Inc. grew its holdings in shares of Elevance Health by 331.6% in the 3rd quarter. Physician Wealth Advisors Inc. now owns 82 shares of the company's stock worth $26,000 after purchasing an additional 63 shares during the last quarter. Activest Wealth Management grew its holdings in shares of Elevance Health by 66.7% in the 3rd quarter. Activest Wealth Management now owns 85 shares of the company's stock worth $27,000 after purchasing an additional 34 shares during the last quarter. Rossby Financial LCC grew its holdings in shares of Elevance Health by 110.0% in the 3rd quarter. Rossby Financial LCC now owns 84 shares of the company's stock worth $28,000 after purchasing an additional 44 shares during the last quarter. Motco grew its holdings in shares of Elevance Health by 334.8% in the 3rd quarter. Motco now owns 100 shares of the company's stock worth $32,000 after purchasing an additional 77 shares during the last quarter. Finally, True Wealth Design LLC grew its holdings in shares of Elevance Health by 431.8% in the 3rd quarter. True Wealth Design LLC now owns 117 shares of the company's stock worth $38,000 after purchasing an additional 95 shares during the last quarter. Institutional investors own 89.24% of the company's stock.

Elevance Health Stock Performance

Elevance Health stock opened at $344.64 on Friday. The company has a current ratio of 1.48, a quick ratio of 1.54 and a debt-to-equity ratio of 0.70. Elevance Health, Inc. has a 1 year low of $273.71 and a 1 year high of $427.54. The company has a market cap of $74.84 billion, a PE ratio of 14.66, a PEG ratio of 1.84 and a beta of 0.49. The company's 50-day moving average is $308.96 and its two-hundred day moving average is $331.62.

Elevance Health (NYSE:ELV - Get Free Report) last released its earnings results on Wednesday, April 22nd. The company reported $12.58 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $10.74 by $1.84. Elevance Health had a net margin of 2.62% and a return on equity of 15.58%. The company had revenue of $49.49 billion for the quarter, compared to the consensus estimate of $48.21 billion. During the same period in the prior year, the company posted $11.97 EPS. The company's revenue was up 1.5% compared to the same quarter last year. Elevance Health has set its FY 2026 guidance at 19.850- EPS. Equities analysts anticipate that Elevance Health, Inc. will post 26.79 earnings per share for the current year.

Elevance Health Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, June 25th. Shareholders of record on Wednesday, June 10th will be given a dividend of $1.72 per share. The ex-dividend date is Wednesday, June 10th. This represents a $6.88 dividend on an annualized basis and a yield of 2.0%. Elevance Health's dividend payout ratio is presently 27.39%.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the stock. Weiss Ratings lowered shares of Elevance Health from a "hold (c-)" rating to a "sell (d+)" rating in a report on Monday, February 2nd. Leerink Partners set a $364.00 price target on shares of Elevance Health in a research report on Thursday. Jefferies Financial Group reduced their price target on shares of Elevance Health from $395.00 to $391.00 and set a "buy" rating on the stock in a research report on Monday. Evercore upped their price target on shares of Elevance Health from $345.00 to $360.00 in a research report on Thursday. Finally, Wells Fargo & Company reduced their price target on shares of Elevance Health from $424.00 to $391.00 and set an "overweight" rating on the stock in a research report on Friday, January 30th. Eleven equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $380.42.

Elevance Health News Summary

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Q1 beat and upgraded outlook — ELV reported strong Q1 results (EPS $12.58 vs. estimates) and raised its 2026 adjusted EPS outlook to at least $26.75 while targeting ~12% EPS growth in 2027, which supports earnings upside and margin improvement. Elevance raises 2026 outlook
• Positive Sentiment: Large analyst upgrade — Sanford C. Bernstein raised its price target to $424 and kept an "outperform" rating, implying ~23% upside; a high-conviction bullish call that can attract demand. Bernstein raises PT to $424
• Positive Sentiment: Barclays reiteration of Buy — Barclays stuck with a Buy rating, signaling institutional confidence that can provide support for the shares. Barclays sticks to Buy
• Positive Sentiment: Operational tailwinds noted — Management highlighted medical cost controls and AI-driven margin expansion, and major outlets reported the company raised its annual profit forecast on those controls, reinforcing the positive earnings message. Profit forecast raised on cost controls
• Neutral Sentiment: Mixed analyst PT lifts with conservative ratings — Several firms nudged up targets but kept neutral/hold stances (Goldman to $370 neutral; Deutsche Bank to $363 hold; Evercore to $360 in-line). These raise reference prices but signal measured optimism. Goldman raises PT to $370
• Neutral Sentiment: Jefferies update — Jefferies revised its forecasts after a deeper look at exchange-segment dynamics and trimmed its PT slightly; this is an analyst reshuffle rather than a directional shock. Jefferies updates forecasts
• Negative Sentiment: Investor litigation probe — Law firm Kirby McInerney has opened an investigation into potential securities claims involving Elevance and/or its senior management; legal scrutiny can pressure the stock and raise uncertainty. Kirby McInerney investor alert
• Negative Sentiment: Some broker nuance implies limited near-term upside — Robert W. Baird's update leaves a neutral stance with a lower relative target vs. some peers, noting limited immediate upside which can cap buying interest. Baird adjusts PT

About Elevance Health

Elevance Health, Inc NYSE: ELV is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company's strategic focus on integrated health care and benefit delivery.

Elevance's core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.